VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors: An Open-label, Phase II, Single-arm, Multi-center Trial
Latest Information Update: 14 Jun 2024
At a glance
- Drugs Atezolizumab (Primary) ; Irinotecan (Primary) ; Irinotecan (Primary) ; Temozolomide (Primary) ; Temozolomide (Primary) ; Vincristine (Primary)
- Indications CNS cancer; Rhabdomyosarcoma; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 18 Apr 2023 Status changed from not yet recruiting to recruiting.
- 27 Feb 2023 Planned number of patients changed from 30 to 23.
- 27 Feb 2023 Planned initiation date changed from 1 Jan 2023 to 1 Mar 2023.